Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of CAD 202.75 billion. The enterprise value is 226.06 billion.

Market Cap	202.75B
Enterprise Value	226.06B

Important Dates

The last earnings date was Friday, August 1, 2025.

Earnings Date	Aug 1, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.68%
Shares Change (QoQ)	-0.32%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.24B

Valuation Ratios

The trailing PE ratio is 23.56 and the forward PE ratio is 14.02.

PE Ratio	23.56
Forward PE	14.02
PS Ratio	5.15
PB Ratio	7.59
P/TBV Ratio	n/a
P/FCF Ratio	15.87
P/OCF Ratio	15.06
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.73, with an EV/FCF ratio of 17.69.

EV / Earnings	26.26
EV / Sales	5.67
EV / EBITDA	11.73
EV / EBIT	14.85
EV / FCF	17.69

Financial Position

The company has a current ratio of 1.32, with a Debt / Equity ratio of 1.27.

Current Ratio	1.32
Quick Ratio	0.97
Debt / Equity	1.27
Debt / EBITDA	1.79
Debt / FCF	2.66
Interest Coverage	11.04

Financial Efficiency

Return on equity (ROE) is 33.40% and return on invested capital (ROIC) is 16.02%.

Return on Equity (ROE)	33.40%
Return on Assets (ROA)	12.62%
Return on Invested Capital (ROIC)	16.02%
Return on Capital Employed (ROCE)	24.77%
Revenue Per Employee	2.24M
Profits Per Employee	489,052
Employee Count	17,600
Asset Turnover	0.53
Inventory Turnover	3.22

Taxes

In the past 12 months, Gilead Sciences has paid 1.21 billion in taxes.

Income Tax	1.21B
Effective Tax Rate	12.36%

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	23.18
200-Day Moving Average	n/a
Relative Strength Index (RSI)	58.79
Average Volume (20 Days)	3,744

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.72

Income Statement

In the last 12 months, Gilead Sciences had revenue of CAD 39.37 billion and earned 8.61 billion in profits. Earnings per share was 6.83.

Revenue	39.37B
Gross Profit	30.91B
Operating Income	15.04B
Pretax Income	9.82B
Net Income	8.61B
EBITDA	18.82B
EBIT	15.04B
Earnings Per Share (EPS)	6.83

Full Income Statement

Balance Sheet

The company has 8.26 billion in cash and 34.02 billion in debt, giving a net cash position of -23.15 billion.

Cash & Cash Equivalents	8.26B
Total Debt	34.02B
Net Cash	-23.15B
Net Cash Per Share	n/a
Equity (Book Value)	26.72B
Book Value Per Share	21.60
Working Capital	4.81B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 13.46 billion and capital expenditures -680.57 million, giving a free cash flow of 12.78 billion.

Operating Cash Flow	13.46B
Capital Expenditures	-680.57M
Free Cash Flow	12.78B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 78.53%, with operating and profit margins of 38.22% and 21.87%.

Gross Margin	78.53%
Operating Margin	38.22%
Pretax Margin	24.95%
Profit Margin	21.87%
EBITDA Margin	47.82%
EBIT Margin	38.22%
FCF Margin	32.46%

Dividends & Yields

Gilead Sciences does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	62.75%
Buyback Yield	-0.68%
Shareholder Yield	n/a
Earnings Yield	4.25%
FCF Yield	6.30%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Gilead Sciences has an Altman Z-Score of 3.47 and a Piotroski F-Score of 7.

Altman Z-Score	3.47
Piotroski F-Score	7